Integrated networks of doctors, patients, and hospitals are a major technique of cancer governance. They enable stakeholders to pool information and resources and achieve systematic learning. Two groups, the childhood cancer group in the US and the Europe Against Cancer initiative, are examples of network governance. Both demonstrate learning processes, production of new data and dissemination, financial support and engagement of all stakeholders. Why have these integrated networks been successful while so many others have failed? Because both are embedded within regulatory frameworks that ensure that networks work properly. Integrated networks are vulnerable when the frameworks fail to provide the necessary accountability, fairness and participation.
Introduction:
The fight against cancer is now a timely topic. President Obama in his State of the Union address endorsed a renewed fight.
a Elizabeth Edwards listed it as the next big item for the Obama administration in the second half of his term. b In part the political proposals for a renewed fight are based on the fact that the results of the first war have been disappointing. Cancer is now the number one cause of death in the United States. The response to the political attention from a President Barrack Obama, State of the Union Address (Jan. 27, 2010 This paper is an interdisciplinary and international comparative study. The authors include a political scientist, a law professor and medical oncologist. The team included experts on the organization of cancer and health care in European Union and the United States. The authors researched the two fights against cancer that have been in process over the past several decades.
The authors used archival research of governmental reports, analyzed medical studies, looked at the regulation and legal literature and conducted in face interviews.
The paper is based on an analysis of two successful projects to improve cancer care
outcomes. The first project is the childhood cancer group based in the United States. The second is the European Union fight against cancer. The paper documents how well-organized networks of experts using data and coordinating research and clinical care can obtain good results. It also demonstrates that when the broader institutional support for these networks is weakened, the ability to continue to produce good results declines. It is a counter-intuitive result for many who do not see how governmental action and structures can produce better results for cancer patients.
In recent months an important study just was issued by the prestigious Institute of Medicine on cancer trials that pinpointed poor results in cancer trials to the ill-coordinated and organized system currently functioning. e The fact that this report has been widely reported and discussed in both the popular and medical media indicates that there may be emerging a broader understanding that legal and policy tools are important aspects in achieving better care and outcomes. 'N 1084 (2010) (arguing that in evaluating the result of the war on cancer, critics should take into consideration the fact that cancer is "a pleomorphic, complex, and highly adaptable disease," and that the aging population makes cancer statistics look worse than it actually is). The paper is organized in four sections. The first section discusses the history of the institutional fights against cancer in the United States and the European Union. The second section describes two integrated networks that are linked to the governmental fights against cancer. The childhood cancer group is the US based example and the Europe Against Cancer is the EU example. The section describes how these networks shared three aspects that contribute to their effectiveness: production of data and dissemination of data, financial support for research and treatment and engagement of stakeholders. Section three describes how regulatory frameworks in which networks are embedded are necessary for continued improvement and learning. The section shows how regulatory frameworks can provide accountability for performance, coordinate stakeholder participation, support physician decision-making and guarantee fairness of data. However, if the regulatory frameworks failed to adequately accomplish the tasks and utilize the available governance tools, the networks, will not achieve their potential. The final section discusses how in the United States and the European Union there is an emerging understanding that as the fight against cancer is renewed, institutional structures and regulation are key tools. The frameworks must be strengthened. In both regions, medical and political leaders are initiating legislative and regulatory initiatives.
I The Early United States and European Union Context
The history of United States and the European Union cancer programs demonstrate how governance can affect cancer outcomes. In both regions, there has been a vision of regulatory frameworks that would enable the production of new knowledge, transference of that knowledge, and utilization in patient care. The motivating force behind this vision was networks of medical experts and important political leaders.
In production of data and dissemination of knowledge; financial support for research and treatment;
and engagement of all stakeholders.
A. Production of Data and Dissemination of Knowledge.
An effective system of information gathering and dissemination is essential for systematic learning. In the area of cancer care, this purpose is often achieved through clinical trials, in particular phase III trials. The use of clinical guidelines is essential to the dissemination of knowledge produced in clinical trials. The childhood cancer group, along with several other cooperative groups, publishes trial results and preferred treatment protocols to their members. The childhood cancer group routinely produces, revises and distributes clinical guidelines to ensure that most children q See Briatte, supra note 12, at 16-19 (discussing that the poor health performance of the UK, illustrated by the EUROCARE-2 study, pushes the UK government to spend more attention and money toward the NHS, cancer services in particular, in an attempt to avoid political blame). 
III. Why Regulatory Frameworks Are Necessary
The success of the two networks is based both on the early visionary regulatory frameworks and the new practices that allow integrating learning and standardization. The regulatory frameworks, the National Cancer Act and the EAC, were crucial in the early development of two integrated networks: the childhood cancer group and European-wide cancer programs. However, in recent years, there is a reduction in the effectiveness of the US and the EU cancer programs.
The ineffectiveness is based in part on the weakening of the regulatory framework. In recent decades, the U.S. regulatory framework created in the 1970s shifted away from translational research and from systematic coordination. NCI delegated the goal of connecting research and clinical care to institutions like comprehensive cancer centers and cooperative research groups.
The collaboration between researchers and clinicians proved spotty and difficult to maintain.
ii Moreover the record of achievement is not impressive. The reductions in cancer mortality have been relatively weak compared to more rapid progress in heart disease and other major health threats. Progress across different types of cancers and across geographic areas has been uneven, with mortality and disability substantially reduced for some but not for others. Why were these outstanding networks unable to stabilize or serve as exemplary projects on their own? The reason is that the regulatory frameworks in which they were embedded proved essential to continued existence and integration. Once these frameworks fail to function effectively, the networks become isolated and fragile. In the case the childhood cancer group, the fragmentation of the cancer institutions originally coordinated by the National Cancer Institute left the childhood cancer group isolated. In the EAC, the cut-off of minimum resources from EU research funds and shift in priorities from cancer to other health issues left the network under resourced.
What are the essential elements that these frameworks provide? The frameworks can include a mix of governmental agencies, health care institutions, non-profit organizations, and private companies. These frameworks can be defined as institutional conditions that create, support, and maintain the well functioning of an integrated learning process. These frameworks support the web of relationships that make up the networks. They also ensure the viability and trustworthiness of the networks. First, the frameworks provide accountability for performance quality. Secondly, they monitor the openness and accessibility of the stakeholder participation.
Thirdly, they remove the economic and others barriers that discourage physicians from participating the learning process. Finally, they guarantee fairness in the process in the creation nn Nass, Moses & Mendelsohn, supra note 5, at 2. Also see generally Young, supra note 6.
oo Trubek, Nance & Hervey, supra note 11, at 811-4. and provision of the data.
A. Ensuring Accountability for Performance in Networks.
Networks promote the creation of data to support the production and dissemination of relevant knowledge. In the case of the childhood cancer group and the EAC, the networks themselves worked to expand the availability of data, convert it into knowledge, and disseminate that knowledge. An effective framework can ensure that the networks continually improve data collection and dissemination and that their learning is shared with other networks. They do this through emphasizing coordination, creating and publishing performance measures and monitoring the dissemination of positive results and protocols.
Coordination
The path to system improvement requires policy and program coordination at multiple levels 
Performance assessment
Coordination is particularly important for a framework to provide multi level monitoring.
Many actors in the cancer network believe that measuring the quality of cancer care is an essential first step towards improving the quality of that care. Without performance indicators, it is argued, there is no way to distinguish the difference between excellent, good, adequate, and inadequate care and, thus, no basis on which to identify strengths and weaknesses in the system to design improvements. Public reporting and pay-for-performance are two relatively "soft" regulatory initiatives emerging in some healthcare networks designed to measure the quality of care and provide incentives for quality improvement. It is well established that performance information like rankings and report cards can have a "purposeful" use in improving existing programs and service delivery. "The doctrine of performance management promised a more efficient and accountable public sector. Performance data would be used to better allocate resources, make decisions about strategy, reengineer processes, motivate workers, and usher in a new era of accountability." rr The potential impact, however, depends on whether the incentives established by performance measures are properly aligned with the goals-in this case, reducing the incidence of cancer, mortality, and disability.
Within the cancer network in the U.S., however, utilization of these tools has been limited to measuring how well providers adhere to cancer screening protocols. For example, data is collected to determine whether physicians are performing mammography, PSA or PAP smear exams at the appropriate time and intervals for individual patients. Experts are optimistic that effective indicators can also be identified to evaluate the quality of cancer care. According to comparative measures.
Systems for Disseminating Results throughout the region
In the United States, most cancer patients are treated in community oncology clinics and hospitals. However, cancer centers never had an integrated system to incorporate information gained through basic and translational research into community oncology practices until the establishment of the National Comprehensive Cancer Network (NCCN) in 1995. The NCCN is an alliance of 21 of the nation's leading cancer centers, which collaborated independent of NCI funding to develop and disseminate clinical practice guidelines in oncology. "We decided a long time ago that we would make our guidelines available, not only to our academic centers but also to community oncologists and whoever else might be able to use them in decision-making. almost entirely attributable to the advocacy influence. ccc Similarly, the patient advocacy associated with the EAC strengthened the political and policy power of the EAC programs both at the EU level and within the member states. The ability of the EAC to interest patients in participating in their work was motivated by the strong commitment of the EU commission to the cancer program. The patient groups in the EU and the member states recognized that their work was encouraged by the EU and often funded by the EU. When the EU funding lapsed in 2002, the patient groups organized to refund the efforts and elevate cancer control again as a major issue on the EU agenda. They realized that without that framework, their influence would
wither. The involvement achieved by integrated networks however, goes much deeper than fundraising or serving on advisory committees. The networks demonstrates that when patients are an integral part of the research project as well as collaborate in treatment, the system could deliver a positive learning cycle that can lead to improving outcomes. Although the traditional patient advocacy performs the needed functions of fundraising and legislation, the learning process itself can function best when patients become active partners of the cancer care system.
A robust regulatory framework can motivate broad stakeholder participation and ensure that the participation is continuous and equitable. This is especially true for patient participation. The childhood cancer group was formed initially because there were not enough patients for individual investigators to conduct meaningful research. Such an intolerable status quo motivated entrepreneurial pediatric oncologists to pool resources and share information with each other.
They also developed a system to engage patients and achieve impressive level of clinical trial participation. Similar conditions do not exist in other cancer networks, and intentionally designed incentives may be necessary to engage stakeholders. While some of the critical stakeholders in the national cancer effort have something to gain by engaging in the learning process, others through consumerism and mechanism like quality report cards. Patients who use report cards "act as consumers, in the sense that they weigh information gathered outside of a pre-existing clinical relationship in selecting a new provider." Kristin Madison, Patients as "Regulators"? Patients' Evolving Influence Over Health Care Delivery, 31 J. LEGAL MED. 9, 19-20 (2010 
IV. Reconstituting the Regulatory Framework
There is an effort underway to reconstitute the frameworks. In the US the attention to the standardization. Both initiatives also emphasize dissemination of knowledge throughout their region to achieve equitable care for all cancer patients. These two initiatives promise a better fight against cancer.
Conclusion
This paper argues that regulatory frameworks are necessary for networks to work properly.
Integrated networks are vulnerable when the frameworks fail to provide the necessary accountability, fairness and participation. This research coincides with the emergence of a substantial literature on how checklists, evidence-based medicine and performance-incentives play a role in improving medical care. ttt This literature has raised awareness that regulatory institutions affect the quality of medical care. The authors of this paper believe that interdisciplinary research can provide useful information and lead us to suggestions on how to improve the current cancer governance system. This research attempts to illuminate specific instances where disease treatment intersects with legal institutions, legislative enactments, government regulation and public-private organizations. Understanding the importance of governance in health outcomes is a needed and crucial enterprise.
ttt See generally ATUL GAWANDE, THE CHECKLIST MANIFESTO-HOW TO GET THINGS RIGHT (2010) (making the case that the use of simple checklists before medical procedures can significantly improve outcomes).
